Main Newsletter
Mastery Series
Therapy Series
 
Bookmark and Share | Print Article | Items for the Week Previous | All Articles This Week | Next
This article originally posted and appeared in  Safety and Error PreventionMedicationIssue 724

Emergency Recall of the OTC Weight-loss Drug Alli

Several reports of tampering have been made nationwide.... 

Advertisement

Multiple reports of tampered Alli products have been reported throughout the United States, prompting an emergency recall of this OTC weight-loss drug.

Reports of tampered bottles containing different types of pills, in various shapes and colors, first began to pour in on Wednesday from consumers in Alabama, Florida, Louisiana, Mississippi, New York, North Carolina and Texas. Many of these bottles were missing labels, packed in a sealed box, and had tamper-evident seals that did not appear genuine.

The manufacturer, GlaxoSmithKline, is currently working with the U.S. Food and Drug Administration in their investigation. The stage in the supply chain where the productions were tampered with still remains unknown.

Product tampering is a serious crime in America and finding the source of this is essential. According to a spokeswoman for GlaxoSmithKline, "The investigation is ongoing... We've asked people to return bottles to us, so we can examine them very closely ... we don't have any theories at this point."

The contents found within the tampered Alli products are currently unknown. As of now, at least 20 inquiries have been made. No reports of harm have been reported.

Practice Pearls:
  • Alli is an OTC weight-loss supplement currently approved for obesity in adults in conjunction with a healthy diet
  • Weight-loss supplements are popular throughout the U.S. and many patients may be using them
  • Anyone who has purchased Alli® and believes it has been tampered with should contact the FDA and manufacture immediately

Hirschler B, Goodman D. GSK recalls weight-loss drug Alli in U.S. on tampering concerns. 

Advertisement


 

Bookmark and Share | Print | Category | Home

This article originally posted 10 April, 2014 and appeared in  Safety and Error PreventionMedicationIssue 724

Past five issues: Diabetes Clinical Mastery Series Issue 208 | Issue 748 | GLP-1 Special Editions September 2014 | Diabetes Clinical Mastery Series Issue 207 | Issue 747 |

2014 Most Popular Articles:

Abbott Announces Approval of Its New Unique Continuous Glucose Monitor
Posted September 05, 2014
Low Carb Beats Low Fat
Posted September 05, 2014
FDA Approves Bupropion/Naltrexone (Contrave) for Obesity by Orexigen Therapeutics
Posted September 12, 2014
Lilly's Basal Insulin Peglispro Demonstrated HbA1c Superiority against Lantus
Posted September 05, 2014
An Exclusive Interview with Al Mann, Founder and CEO, Mannkind Corp.
Posted September 15, 2014
Sleeve Gastrectomy Now a Common Choice for Bariatric Surgery
Posted September 12, 2014
Type 2 Diabetes Diagnosis Needs to Be Changed: Prediabetes=Diabetes
Posted September 12, 2014
Predicting Which Diabetics Will Develop Major Complications
Posted September 05, 2014
Empagliflozin (Jardiance) SGLT-2 Inhibitor Now Available in Pharmacies
Posted August 29, 2014
High-salt Diet and High HBA1c May Increase Cardiovascular Disease
Posted September 19, 2014


Browse by Feature Writer & Article Category.
A. Lee Dellon, MD | Aaron I. Vinik, MD, PhD, FCP, MACP | Beverly Price | Charles W Martin, DD | Derek Lowe, PhD | Dr. Bernstein | Dr. Brian Jakes, Jr. | Dr. Fred Pescatore | Dr. Tom Burke, Ph.D | Eric S. Freedland | Evan D. Rosen | Ginger Kanzer-Lewis | Greg Milliger | Kristina Sandstedt | Laura Plunkett | Leonard Lipson, M.A. | Louis H. Philipson | Maria Emanuel Ryan, DDS, PhD | Marilyn Porter, RD, CDE | Melissa Diane Smith | Michael R. Cohen, RPh, MS, ScD, FASHP | Paul Chous, M.A., OD | Philip A. Wood PhD | R. Keith Campbell, Professor, B.Pharm, MBA, CDE | Sheri R. Colberg PhD | Sherri Shafer | Stanley Schwartz, MD, FACP, FACE | Steve Pohlit | Steven V. Edelman, M.D. | Timothy S. Hollingshead |

Cast Your Vote
Now that once-weekly dulaglutide has been approved, will you be prescribing it?
CME/CE of the Week
Jeffrey M. Robbins, DPM

Category: Vascular Therapy
Credits: .75


Advertisement


Search Articles On Diabetes In Control